Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

Inclusion Criteria: * Ability to understand and voluntarily sign an informed consent form * Age \> 18 years at the time of signing the informed consent form * Pathological confirmation of leukemia or myelodysplastic syndrome. * AML according to WHO criteria; except for core-binding factor AMLs (t(8;21), inv(16) or t(16;16)) and APL * ALL * MDS * Patients with AML include the following: * Patients in 2nd or greater relapse * Patients in first relapse with initial CR duration lasting \<6 months * Patients in first relapse refractory to induction therapy * Patients with primary refractory AML * Patients with ALL include the following * Patients with T-cell ALL refractory or in relapse following nelarabine * Patients with other ALL that is refractory or in relapse. * Patients with MDS include the following: * The subset of RAEB-2 patients with \>10% blasts with at least 1 prior therapy that includes a hypomethylating agent. * Previously untreated chemotherapy induced AML * Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1 or 2 * Able to adhere to the study visit schedule and other protocol requirements * Life expectancy of at least 12 weeks * Laboratory values fulfilling the following: * Serum creatinine \< 1.5 mg/dL * Serum total bilirubin \< 1.5 mg/dL * Serum alanine aminotransferase or aspartate aminotransferase \< 150 IU/liter Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss. * Cardiac ejection fraction \> 50% by MUGA scan or echocardiography * All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile. Exclusion Criteria: * Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent form * Chemotherapy or other investigational anticancer therapeutic drugs in the two weeks prior to study entry; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to 24 hours before study entry * Clinical evidence of active CNS leukemic involvement * Pregnant or lactating women * Clinically significant cardiac disease (New York Heart Association Class III or IV) * Severe debilitating pulmonary disease * Active and uncontrolled infection. Patients with an infection under active treatment with antibiotics and whose infection is controlled may be entered into the study * Current evidence of invasive fungal infection (blood or tissue culture); HIV or hepatitis C infection * Hypersensitivity to cytarabine, daunorubicin or liposomal products * History of Wilson's disease or other copper-related disorder